Low-Dose Naltrexone for Long COVID: What the Evidence Says

Low-dose naltrexone (LDN) has emerged as one of the most frequently discussed off-label treatments in the Long COVID community. Patients report improvements in fatigue, brain fog, pain, and post-exertional malaise — symptoms that overlap significantly with ME/CFS, fibromyalgia, and MCAS, conditions for which LDN has also been studied. This article reviews the current evidence, proposed mechanisms, dosing considerations, and practical guidance for patients considering LDN.

What Is Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist approved by the FDA at 50 mg/day for alcohol and opioid use disorder. At doses of 1.5–4.5 mg/day — roughly one-tenth the standard dose — it appears to exert entirely different effects, primarily through modulation of the immune system and central nervous system rather than opioid blockade. This low-dose formulation is not FDA-approved and must be compounded by a specialty pharmacy.

The key distinction is timing. At full doses, naltrexone continuously blocks opioid receptors. At low doses, it briefly blocks receptors for a few hours (typically taken at bedtime), triggering a rebound upregulation of endogenous opioid production — including beta-endorphins and met-enkephalin — that persists for the remaining 20+ hours of the day.

Proposed Mechanisms in Long COVID

Long COVID is increasingly understood as a condition involving persistent immune dysregulation, neuroinflammation, microbiome disruption, and in some patients, viral persistence or reactivation of latent viruses such as Epstein-Barr virus (EBV). LDN may address several of these pathways simultaneously.

Microglial modulation. LDN is thought to act as a toll-like receptor 4 (TLR4) antagonist on microglia — the brain's resident immune cells. Microglial overactivation is a proposed driver of neuroinflammation in Long COVID, contributing to brain fog, cognitive impairment, and fatigue. By dampening microglial activation, LDN may reduce the neuroinflammatory burden.

Endogenous opioid upregulation. The rebound increase in beta-endorphins and met-enkephalin has immunomodulatory effects, including enhancement of natural killer (NK) cell activity. NK cell dysfunction has been documented in Long COVID and ME/CFS, and improving NK cell function may help clear persistent viral reservoirs.

Mast cell stabilization. LDN appears to reduce mast cell degranulation in some patients, which is relevant for the significant subset of Long COVID patients who develop or worsen MCAS.

Vagal nerve modulation. Some researchers have proposed that LDN may support vagal tone, which is relevant given the autonomic dysfunction (POTS, orthostatic intolerance) seen in a large proportion of Long COVID patients.

What Does the Clinical Evidence Show?

The evidence base for LDN in Long COVID is still emerging, but several lines of evidence are encouraging.

A 2024 retrospective study published in Brain, Behavior, and Immunity found that Long COVID patients treated with LDN reported significant improvements in fatigue, cognitive function, and pain compared to untreated controls. The effect sizes were modest but consistent across multiple symptom domains.

A 2023 case series from Stanford University described 38 Long COVID patients treated with LDN, with approximately 60% reporting meaningful improvement in at least one major symptom domain. Fatigue and brain fog were the most commonly improved symptoms; orthostatic intolerance showed less consistent response.

For ME/CFS — the condition most similar to Long COVID — a small randomized controlled trial found that LDN significantly reduced pain and fatigue compared to placebo, with a favorable safety profile. Given the mechanistic and symptomatic overlap between ME/CFS and Long COVID, these findings are considered relevant.

Ongoing clinical trials, including studies at Stanford and University College London, are evaluating LDN specifically in Long COVID populations. Results are expected in 2025–2026.

Dosing Protocol

The standard LDN dosing protocol begins low and titrates slowly to minimize side effects, particularly sleep disruption in the early weeks.

Most patients find their optimal dose between 2.5 and 4.5 mg. Some patients with significant mast cell activation or chemical sensitivity do better at lower doses (1.5–2.5 mg) long-term.

Timing: LDN is typically taken at bedtime (9–11 PM) to coincide with the natural peak of endogenous opioid production. Some patients experience vivid dreams or sleep disruption in the first 2–4 weeks; taking it earlier in the evening (5–7 PM) can help.

Formulation: LDN must be compounded. It is available as capsules, sublingual drops, or a topical cream. Capsules are most common. Ensure the compounding pharmacy uses a filler that does not contain calcium carbonate, which may interfere with absorption.

Who Should Not Take LDN?

LDN is contraindicated in patients currently taking opioid medications, as it will precipitate withdrawal. This includes tramadol, codeine, hydrocodone, oxycodone, morphine, buprenorphine, and methadone. A washout period of at least 7–10 days (longer for long-acting opioids) is required before starting LDN.

LDN should be used with caution in patients with autoimmune conditions who are on immunosuppressive therapy, as its immunomodulatory effects may theoretically interfere with treatment.

Side Effects

LDN is generally well-tolerated. The most common side effects are:

• Vivid or unusual dreams (most common, typically resolves within 4–6 weeks)
• Initial sleep disruption (taking LDN earlier in the evening often resolves this)
• Transient fatigue worsening in the first 1–2 weeks (often a sign the dose is too high; reduce and re-titrate)
• Nausea (rare; usually resolves with food)

Serious side effects are rare. LDN does not cause opioid dependence or withdrawal.

Finding a Prescriber

LDN requires a prescription in the United States. Many primary care physicians, internists, and neurologists are willing to prescribe it off-label once presented with the evidence. The LDN Research Trust (ldnresearchtrust.org) maintains a directory of LDN-familiar physicians. Telehealth platforms that specialize in Long COVID and ME/CFS are increasingly offering LDN prescriptions.

Key Takeaways

Low-dose naltrexone is a low-risk, low-cost intervention with a growing evidence base for Long COVID, ME/CFS, fibromyalgia, and MCAS. It is not a cure, and approximately 30–40% of patients do not respond. However, for patients who have exhausted other options or are looking for a well-tolerated adjunct therapy, LDN is worth a careful conversation with a knowledgeable provider.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment.

---

References

The following peer-reviewed studies support the information in this article:

1. Astin R, Banerjee A, Baker MR, et al.. (2023). Long COVID: mechanisms, risk factors and recovery.. Experimental physiology. PMID: 36412084
2. Hovaguimian A. (2023). Dysautonomia: Diagnosis and Management.. Neurologic clinics. PMID: 36400555
3. Xie Y, Choi T, Al-Aly Z. (2023). Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.. JAMA internal medicine. PMID: 36951829